<DOC>
	<DOCNO>NCT02646735</DOCNO>
	<brief_summary>A Randomized , Open label , Parallel-group , Multi-center study . Eligible patient randomize 1:1 ratio receive fulvestrant 500 mg Exemestane 25mg .</brief_summary>
	<brief_title>Fulvestrant 500mg With Exemestane Endocrine Therapy Postmenopausal Advanced Breast Cancer Patients</brief_title>
	<detailed_description>To compare efficacy tolerability Fulvestrant 500 mg Exemestane 25 mg first line endocrine therapy postmenopausal woman oestrogen receptor positive HER2 negative advance breast cancer relapse adjuvant non-aromatase inhibitor therapy</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Signed informed consent document file ; Age 60 year ; Age &lt; 60 year amenorrheic 12 month absence chemotherapy , tamoxifen , toremifene , ovarian suppression FSH oestradiol level postmenopausal range ; Patients metastatic locally advanced disease amenable therapy Curative intent ER + and/or PgR + ; Duration adjuvant nonaromatase inhibitor treatment least 2 year ; WHO performance status 0 , 1 2 ; Patients life expectancy 3 month . Presence lifethreatening metastatic visceral disease ; Previous systemic chemotherapy advance breast cancer ; Received systemic endocrine therapy advance disease ; Extensive radiation therapy within last 4 week ; Platelets &lt; 100*109 / L , Total bilirubin less 1.5ULRR , ALT AST le 2.5ULRR demonstrable liver metastases less 5ULRR presence liver metastases ; Severe renal impairment , bleed diathesis , longterm anticoagulant therapy ; History hypersensitivity active inactive excipients fulvestrant , Exemestane and/or castor oil .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>